The indivisible self has become divided. Divided by the structures of medical specialism which themselves reflect the understanding of a wider society. Divided too by a mind and body philosophy that prefers reductionism to holism. More recently, divided by healthcare management struggling to address the issues of integrated care for patients who place multiple physical and mental health care demands upon a system so often seeming to be at breaking point.

In spite of forces which divide the self, recent years have seen some convergence in physical and mental health care. In psychiatry, there has been an increasing awareness of the need to address the physical health issues of patients. Primary care too has adopted a more holistic agenda promoting the concept of ‘medical generalism’ encompassing the medical, psychological and social agenda of patients.

The size of the mortality gap
The mortality gap for patients with schizophrenia has been apparent since the 17th century in observations on the mortality of ‘lunacy’. A gap of about 20 years for men and 15 years for women is still experienced by patients with psychosis in the developed world. Reporting a somewhat smaller mortality gap of 13 years for males and 12 years for males, Chang et al found that schizophrenia, schizoaffective disorder and bipolar disorder contributed similarly to observed excess mortality values whereas patients with substance use disorders had a larger mortality gap.

The cause of the mortality gap
The causes of the mortality gap can broadly be divided into four categories. Firstly, patients with Serious Mental Illness (SMI) have a higher rate of suicide, accidental or violent death. Secondly, several risk factors combine to adversely affect health such as smoking, lower levels of exercise, obesity (which itself may be the iatrogenic consequences of anti-psychotic medication). These, in turn, increase the rates of cardiovascular disease, COPD and cancers (as well as the cancer risk associated with smoking, we now know that obesity contributes to 11 types of cancer); they are also linked to social deprivation and the broader determinants of SMI. Thirdly, antipsychotic
medication itself adds to the burden of long term conditions (LTCs) mediated by iatrogenic weight gain, hyperlipidaemia and diabetes. Finally, patients with SMI experience reduced access to healthcare either through delayed presentation, reduced uptake of health screening and preventative care, difficulty coping with the demands of LTC monitoring and treatment, or mis-attribution of symptoms. Both patients and health professionals may interpret symptoms of physical disease, possibly even red flag symptoms, as just another manifestation of their SMI, a process known as ‘diagnostic overshadowing’. Finally, stigmatising attitudes towards people with severe mental illnesses, held by healthcare professionals, may play a significant role.

Of all the causes of the mortality gap, mental health services often focus on the less common causes of suicide and violent death. In fact, excess mortality is predominantly the result of cardiovascular, respiratory or malignant disease. Of all the causes of the mortality gap, mental health services often focus on the less common causes of suicide and violent death. In fact, excess mortality is predominantly the result of cardiovascular, respiratory or malignant disease.5

Comparisons with other mortality gaps
The importance of the SMI mortality gap can be seen by comparing it with that for other conditions commonly within the remit of GPs. For example, the mortality gap attributable to smoking has been put at two to three years in the US or around seven years in New Zealand (cited in Chang et al3). For type 2 diabetes the gap has been estimated at 1.3 to 2.0 years (for men and women, respectively) (cited in Chang et al3).

Direction of the mortality gap
It might be thought that with improvements in psychiatric care, in medical care and in the wealth of society, the SMI mortality gap would slowly decrease. Evidence is now emerging that far from narrowing, the gap has widened. In a 30-year study from Denmark, mortality in the general population had fallen substantially such that life expectancy was, on average, 6.3 years higher.6 In contrast, over the same period life expectancy in the schizophrenia population declined by 1.3 years. These findings were accompanied by much concern that observed deterioration had occurred in a society with a strong health care system and pride in the equality of its social structures. One possible explanation offered was that closure of in-patient psychiatric facilities had not been accompanied by parallel increases in the provision of community mental health services. In a UK study over the period 2000 to 2014, all-cause mortality for patients with SMI fell. For patients with bipolar disorder, the decline was at a similar rate to the overall population rate of decline. For patients with schizophrenia, the decline was slower, thus resulting in a widening of the mortality gap.7
Challenges of addressing the physical health of SMI patients

Shared physical health care of SMI patients between primary and community services is likely to become increasingly common, driven both by patient choice (some may choose only to access care through their GP, others only through mental health services) and relatively recent NICE guidance which recommends that the mental health team should maintain responsibility for monitoring users’ physical health for at least 12 months after starting antipsychotic medication. In practice, health promotion and LTC management are core competencies for GPs who are likely to play a leading role in addressing physical health issues in SMI patients. QOF (the Quality and Outcomes Framework) is unlikely to offer a sufficient infrastructure for guiding physical health care especially since serum HbA1c and cholesterol monitoring were removed as SMI indicators in April 2014. The King’s Fund have highlighted the importance of prioritising the needs of SMI patients at CCG (Clinical Commissioning Group) level with the provision of tailored services for long term conditions and for smoking cessation. In other words, instead of a focus on achieving overall population targets for cardiovascular health, pulmonary rehabilitation, smoking cessation and so on, the focus needs to shift to SMI patients to ensure that they are not excluded from quality targets.

We know that smoking is the largest cause of preventable death in the UK. The situation is no different for patients with SMI. However, bespoke smoking cessation services for SMI patients are not widely available and interventions have been hampered by lingering concern that treating nicotine addiction might have adverse effects on the underlying mental state. A survey of the literature concluded that treating tobacco dependence is effective in patients with SMI and that treatments are equally effective as for the general population; moreover, there was no evidence of worsening mental state in those with ‘stable psychiatric conditions’. Efforts to address smoking cessation are all the more urgent in SMI patients since smoking rates are three times that of the general population and at the same time, these patients are less likely to receive smoking cessation support. Here is a clear opportunity for primary care to make a difference.

The ultimate challenge is to achieve parity. Parity of physical health care in patients with and without SMI. Primary care in the UK is well positioned to narrow that yawning (and possibly widening) gap through its focus on whole person care. The divided self may be a little less divided if patients with SMI can access more holistic care.
References:


